ArticleAdvances in nutrition (Bethesda, Md.)2026
The Incretin Mirage: Epigenetic Memory as a Potential Driver of Post-Treatment Weight Regain.
Article in Advances in nutrition (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although incretin receptor agonists deliver profound weight loss, clinical data reveal a consistent challenge: treatment discontinuation routinely triggers rapid weight regain. We define this phenomenon as the "Incretin Mirage"-a state where pharmacologically induced weight reduction temporarily conceals the persistent metabolic and neuroendocrine adaptations established during chronic obesity. Despite a lower body mass, key drivers of the disease, including adipocyte dysfunction and altered appetite signaling, retain a molecular imprint of obesity driven by persistent epigenetic marks. To explain why the body aggressively resists sustained weight loss after treatment cessation, we introduce the "Epigenetic Detent." This novel conceptual mechanism links adipocyte epigenetic memory with neuroendocrine plasticity to preserve a high-adiposity set-point. Consequently, the moment pharmacological suppression is lifted, this persistently defended set-point serves as a potential driver of weight regain. Achieving a durable therapeutic response therefore requires moving beyond transient appetite suppression. We advocate for a coordinated, multitiered strategy that couples lifestyle and environmental restructuring with emerging epigenetic therapies aimed at erasing these cellular marks and achieving a complete cellular metabolic reset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.